Neurotin

Quick links to important sections

Neurotin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neurotin

Quick Facts

Property Description
Active ingredient Acetylcarnitine (ALCAR)
Form Oral Capsules, Intravenous Solution
Pharmacological class Nootropic Agent (Psychoanaleptic)
Common use Metabolic and Neuroprotective Support
Origin Endogenous Derivative (Synthetic production)

Acetylcarnitine: The Core Identity of Neurotin

Neurotin is a trade name associated with pharmaceutical preparations that contain the single active ingredient Acetylcarnitine, commonly abbreviated as ALCAR. The substance is classified as a Nootropic Agent, within the wider category of Psychoanaleptics (ATC code N06BX12). Acetylcarnitine is chemically defined as an acetylated form of L-carnitine, which is an endogenous derivative naturally produced within the human body. This specific chemical structure is recognized for enhancing its ability to efficiently cross the blood-brain barrier, thereby focusing its therapeutic effects within the central nervous system.

Composition, Origin, and Available Forms

The active substance is typically supplied as Acetyl-L-carnitine hydrochloride, formatted as a single-ingredient product. High-level dosage forms include Oral Capsules for ingestion and an Intravenous (IV) Solution for parenteral administration in clinical settings. Although the core molecule is a naturally occurring metabolite essential for energy transport, the preparation utilized in medicine and supplements is generally produced synthetically. Its general neuroprotective properties in supporting cellular health in the nervous system are recognized in pharmacological descriptions of the agent.

What is Acetylcarnitine's General Purpose?

The primary role of Acetylcarnitine is to offer both metabolic and neuroprotective support throughout the nervous system, especially in older adults or individuals facing metabolic challenges. The compound supports nerve cell health by acting as an essential acetyl group donor, a function necessary for the synthesis of the vital neurotransmitter acetylcholine. This mechanism helps ensure nerve cells have the necessary energy and chemical components to maintain normal function, thereby contributing to the sustained health and performance of both central and peripheral nerve tissues. Its established role in mitochondrial function is essential for cellular energy processes.

What side effects are possible with Neurotin?

Acetylcarnitine (Neurotin) is associated with officially documented adverse reactions that are primarily classified according to their frequency and the body system affected, based on regulatory standards. The overall profile is characterized by effects on the digestive and nervous systems.

Official Adverse Reaction Classifications

Adverse reactions are organized into System-Organ Classes (SOCs) in official labeling. The most frequently reported effects often involve:

  • Gastrointestinal Disorders: These may include very common occurrences such as diarrhea, abdominal pain, nausea, and vomiting. Constipation and dyspepsia are also commonly documented.
  • Nervous System Disorders: Common effects include headache, dizziness, and paresthesia. Psychiatric disorders like insomnia and depression are also listed.

Documented Serious Adverse Reactions

The regulatory safety profile highlights the potential for serious, though less frequent, adverse events. These include documented cases of serious hypersensitivity reactions, such as anaphylaxis, which have been reported, particularly following intravenous administration. Additionally, official documents note the potential for an increase in the frequency or severity of seizures in individuals with a pre-existing seizure disorder.

Population-Specific Safety Constraints

The labeling includes specific safety considerations for certain patient populations:

  • Severe Renal Impairment: Patients with severely compromised kidney function or End-Stage Renal Disease (ESRD) face a risk of accumulation of potentially toxic metabolites (trimethylamine and its oxide) with chronic high-dose oral use, as these compounds are normally cleared by the kidneys.
  • Anticoagulant Use: Caution is advised for individuals taking anticoagulants like warfarin, as acetylcarnitine may increase the anticoagulant effect, which may necessitate monitoring of the International Normalised Ratio (INR).

Note on Exposure: While most gastrointestinal effects are mild, they may often lessen or disappear if the dosage is reduced during long-term use, as noted in the regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that specific reports of toxicity from overdosage of the drug's metabolite, Levocarnitine, have not been submitted. The overdose profile is instead defined by the management of high-dose adverse manifestations and documented severe risks.

Documented Overdose Presentations: Administration of large doses may result in mild to moderate gastrointestinal complaints, including diarrhea, nausea, and abdominal cramps, along with a "fishy" body odor. Decreasing the dosage is typically indicated to mitigate these effects.

Urgent Medical Help Required: Urgent medical attention must be sought for the occurrence of severe, documented events affecting the Central Nervous System (CNS) or Immune System. This includes new or worsening seizure activity in patients with pre-existing seizure disorders, or signs of a severe hypersensitivity reaction (e.g., swelling of the throat or difficulty breathing).

Population-Specific and Supportive Measures: For patients with severely compromised renal function or those on dialysis, official warnings exist regarding the risk of accumulation of potentially toxic metabolites. In cases of severe accumulation, regulatory guidance confirms that Levocarnitine is easily removed from the plasma by dialysis, which is a key supportive procedural measure.

Therapeutic Uses of Neurotin

What Neurotin Treats: Main Uses and Benefits

Acetylcarnitine (Neurotin) is commonly used to help manage symptoms associated with various peripheral neuropathies, including those found in patients with diabetes or HIV/AIDS. This intervention is used to help manage symptoms related to physical discomfort, such as burning pain, tingling, and numbness (paresthesia), which are common symptomatic manifestations. The medication is also considered relevant for individuals experiencing mild deficits in mental function, including age-related memory loss or Mild Cognitive Impairment (MCI), and may be applied in situations involving chronic states of mental and physical exhaustion like Chronic Fatigue Syndrome. Acetyl-L-carnitine is utilized for its potential role in addressing peripheral neuropathy.


Key Therapeutic Focus

The supportive use of Acetylcarnitine contributes to easing the overall symptom burden, which may assist with maintaining functional stability and contribute to easing discomfort during symptomatic periods. The medication is primarily applied in scenarios where symptoms interfere with daily functioning and create noticeable physiological strain, and may provide supportive relief to patients facing recurrent or chronic manifestations.

Quick Fact: Supportive Focus
Supportive Focus for: Peripheral Neuropathy, Age-Related Cognitive Symptoms, Chronic Fatigue

Eligibility and Restrictions for Use

Neurotin (gabapentin) is approved for use in specific populations based on condition and age, with contraindications and restrictions defined by regulatory bodies.

Contraindications and Restrictions

  • Contraindication: Neurotin is formally contraindicated in patients with a demonstrated hypersensitivity or allergy to gabapentin or its formulation ingredients.

  • Condition-Specific Restrictions (Use Requires Dose Adjustment): Since the drug is eliminated primarily by the kidneys, use requires mandatory dose adjustment in adults and adolescents (12 years and older) with compromised renal function (kidney impairment). Patients undergoing hemodialysis also require a supplemental dose following each dialysis session.

  • Age-Related Eligibility:

    • Adults: Approved for both postherpetic neuralgia and as adjunctive therapy for partial onset seizures.
    • Pediatric Patients: Approved for use in children 3 years and older as adjunctive therapy for partial onset seizures. Use in children younger than 3 years for this indication is not established.
    • Elderly Patients (over 65): May require dose adjustment due to age-related decline in kidney function. Caution is advised for those with underlying respiratory issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific pharmacokinetic and pharmacodynamic interaction patterns for Acetylcarnitine, which is marketed under the trade name Neurotin. These interactions describe constraints for co-administration with other medicinal products and limitations for use in specific populations.

Documented Pharmacodynamic and Exposure Interactions

The co-administration of Acetylcarnitine with certain drug classes may require procedural monitoring or may reduce the therapeutic effect of the co-administered drug.

Interacting Substance Class Officially Documented Effect Regulatory Restriction
Coumarin Anticoagulants (e.g., Warfarin) May increase the effects of the anticoagulant, documented as an increased International Normalised Ratio (INR). Requires frequent monitoring of INR levels.
Serotonergic Agents May lead to additive effects by increasing brain serotonin levels. Caution advised due to potential for adverse effects.
Thyroid Hormone Replacements May decrease the effectiveness of the thyroid hormone replacement. Potential for reduced efficacy of the thyroid medication.

Population-Specific Constraints

For patients with severely compromised renal function, including those on dialysis, the chronic administration of oral carnitine derivatives, such as Acetylcarnitine, may lead to the accumulation of specific metabolites, including trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). This risk is explicitly noted in official prescribing information due to the impaired renal clearance of these byproducts. There are no mandatory timing separation rules documented for Acetylcarnitine, and no specific interactions with food, alcohol, or herbal products are formally described in regulatory labeling.

Mechanism of Action

The mechanism of Neurotin (Acetylcarnitine) influences key pathways for neuronal signaling and resilience, operating across three core mechanistic domains to modulate molecular and cellular processes.


Optimizing Neuronal Bioenergetics

Acetylcarnitine functions as a vital carrier, shuttling acetyl groups into the mitochondria to fuel the Tricarboxylic Acid (TCA) Cycle through the enzyme Carnitine Acetyltransferase. This action enhances the cell's ability to generate ATP, thereby sustaining the high metabolic capacity required for cellular signaling, particularly under high metabolic demand or oxidative challenge.


Supporting Cholinergic Signaling

The molecule is a direct acetyl group donor used by the enzyme Choline Acetyltransferase (ChAT) to synthesize the key neurotransmitter Acetylcholine (ACh). This mechanism ensures an available supply of the building block necessary to maintain communication across synapses in both the central and peripheral nervous systems, influencing the dynamics of synaptic signal flow.


Neuroprotection and Epigenetic Modulation

The drug acts as an epigenetic modulator by contributing to the nuclear pool of Acetyl-CoA, which facilitates histone acetylation. This process influences the long-term expression of neurotrophic and protective genes, while simultaneously dampening neuroinflammatory signaling by inhibiting the NF-κB pathway. This sustained action influences processes that establish neuronal structural stability and protection against cellular stress.

Dosage and Administration Information

The administration of Acetylcarnitine (Neurotin) is described across two standard routes: the oral route (via capsules) and the intravenous (IV) route for parenteral use. Standard regimens indicate that the medicine is typically used in a divided daily schedule.

General Administration Guidelines

Administration Scope Procedural Requirements and Ranges
Route of Administration Oral or Intravenous (IV).
Dosing Schedule The standard adult total daily dose typically ranges from 2.0 grams to 3.0 grams. Initial intravenous therapy may use up to 3.0 grams daily.
Frequency and Timing The total dose is divided for administration either twice (BID) or three times (TID) daily. Oral doses are generally taken with or immediately following a meal.
Procedural Conditions Intravenous administration involves the solution being delivered slowly, typically over 2–3 minutes, when given as a bolus.
Treatment Duration The regimen often involves a transition from an initial IV course to a long-term oral maintenance phase, with extended use protocols often lasting up to 1 year.

The general use protocol involves the medicine being administered in multiple daily doses to maintain procedural consistency, with the specific route chosen depending on the stage of treatment. These administration constraints—relating to meal timing and the required slow rate of IV delivery—are established in standard clinical protocols to define the method of use. The use protocol for chronic conditions is designed for extended duration, sometimes spanning up to 12 months of maintenance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Acetylcarnitine (Neurotin)


Evidence for use in Painful Peripheral Neuropathy

Acetylcarnitine was studied for its role in conditions presenting with outcomes related to physical discomfort, such as painful nerve symptoms related to Diabetic Peripheral Neuropathy (DPN) and nerve pain was evaluated in settings related to specific chemotherapy treatments. The research landscape includes numerous short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies generally focused on adult populations and used specialized scales to measure how symptoms like pain, burning, tingling, and numbness changed over the study period.

These studies monitored both subjective patient-reported outcomes describing perceived discomfort and objective measures of nerve function, like the speed of nerve signals (Nerve Conduction Velocity or NCV). Studies monitored outcomes related to measured changes on standardized symptom scores compared to control groups in some clinical trials. However, the evidence for all causes of nerve pain is not uniform. Research was observed in some studies to have mixed results when applied to certain nerve conditions.

Certainty remains low for a consistent result across all types of nerve pain. The evidence base includes varying study populations and different underlying causes of nerve damage, which contributes to the research uncertainty.


Evidence for use in Age-Related Cognitive Symptoms

Acetylcarnitine was studied in research exploring how symptoms change over time in older adults with Age-Related Cognitive Symptoms and Mild Cognitive Impairment (MCI). Research examined these areas through double-blind, placebo-controlled clinical trials, and the resulting data was evaluated in systematic reviews. The trials focused on specific measures of mental function, such as memory, attention, and language skills, using standardized cognitive tests.

Some studies monitored changes over several months related to aspects of memory and attention. Research examined varying levels of measured change across populations with different severities of initial cognitive deficit. These studies contribute to the broader evidence landscape.

Evidence quality varies across studies, and the consensus among expert reviewers can be mixed. For the broader range of cognitive disorders, certainty remains low about the findings related to this substance. The results apply only to the populations studied, and the long-term impact on age-related cognitive issues not fully established.

Key Studies & References

  1. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

Frequently Asked Questions (FAQ)

Common questions about Neurotin (FAQ)

Q: Is Neurotin the same medication as gabapentin?

Yes, the brand name Neurotin is used for the drug containing the active ingredient gabapentin. Official product information confirms that gabapentin is the generic name for this medicine.

Q: Is Neurotin a type of opioid or narcotic pain reliever?

According to U.S. federal classification, this medicine is not classified as an opioid or narcotic. Official regulatory information warns that combining it with opioids or other central nervous system depressants is associated with a serious risk of breathing problems.

Q: Does Neurotin typically cause weight gain or weight loss?

Official regulatory documents state that weight gain is a common adverse reaction observed in clinical studies. Regulatory data does not prominently feature weight loss among the most frequently reported adverse reactions.

Q: Is it true that Neurotin can cause swelling in the hands or feet?

Yes, the official product information indicates that swelling of the hands, feet, or lower legs, medically known as peripheral edema, is a common side effect.

Q: Are there any official warnings about taking Neurotin for a long period of time?

Official warnings note that long-term use is associated with common side effects, such as weight gain and fluid retention (edema). Official documentation notes that these may necessitate clinical review, as they are often reported more frequently at higher doses.

Q: Is Neurotin considered a controlled substance in the U.S. or other countries?

The medicine is not federally classified as a controlled substance in the U.S. However, its classification is subject to determination by state and local jurisdictions, with several U.S. states classifying it as a Schedule V controlled substance.

Q: Can Neurotin affect sleep patterns, such as causing insomnia or excessive drowsiness?

Regulatory documents list both drowsiness (somnolence) and insomnia as common side effects. These effects are classified under nervous system disorders in regulatory documents.

Q: Can Neurotin cause confusion or memory problems?

Official information notes that the medicine may cause trouble with thinking. Additionally, the symptom of confusion is documented as a side effect that can occur during withdrawal if the drug is stopped too quickly.

Q: What happens in terms of safety when a person stops taking Neurotin abruptly?

Official safety warnings state that abruptly discontinuing the medicine is associated with the risk of serious adverse reactions, including an increased risk of seizures that will not stop, known as status epilepticus.

Q: Is Neurotin associated with any risk of physical dependence or withdrawal?

Official documentation indicates that physical dependence can develop with regular, prolonged use. For this reason, abrupt reduction or stopping may lead to the occurrence of withdrawal symptoms.

Q: Are there official restrictions on physical activity while taking Neurotin?

Official guidance contains warnings about the risk of dizziness and sleepiness, which may impair an individual's ability to safely drive or operate heavy machinery. Patients are cautioned about engaging in activities requiring full attention.

Q: Does Neurotin affect the effectiveness of oral birth control pills?

Official clinical study data indicates that the medicine is unlikely to cause contraceptive failure when taken alongside combined oral contraceptives.

Q: Can Neurotin cause the side effect of dry mouth?

Yes, dry mouth is explicitly listed in the official regulatory documents as one of the common adverse reactions reported by patients.

Q: How frequently do people experience the more serious side effects of Neurotin?

Official documentation provides incidence rates for common side effects like dizziness and somnolence from clinical trials. Serious adverse reactions, such as anaphylaxis, are typically listed as rare or very rare.

Q: What factors determine if Neurotin is a non-scheduled drug in a particular region?

The medicine is not federally classified as a controlled substance in the U.S., but its scheduling is often determined by state law. This difference means the medicine’s status can vary depending on regional laws.

Q: What is the process for safely discontinuing Neurotin, according to official documents?

Official guidance states that discontinuation must be done gradually over a minimum of 1 week. This process is specified to help mitigate the risk of serious adverse reactions during the transition.

Q: Can Neurotin affect liver function over time?

Official warnings note that a rare, severe allergic reaction known as DRESS syndrome has been reported. This serious reaction has the potential to cause damage to major organs, including the liver.

Q: Can Neurotin cause blurry or double vision?

Official adverse reaction lists include blurred vision (amblyopia) as a common side effect. Double vision has also been reported, with some reports specifically mentioning overdose situations.

Q: Does Neurotin carry a risk for suicidal thoughts or behaviors, as noted in official warnings?

Yes, the medicine carries a prominent warning for an increased risk of suicidal thoughts or behaviors. This warning applies to all patients taking antiepileptic drugs, according to the official Medication Guide.

Q: Does Neurotin change mood or cause emotional instability?

Official warnings describe the risk of new or worsening depression or anxiety in patients. Regulatory documents also note emotional changes (lability) as a potential effect in pediatric patients.

Q: Is feeling dizzy or unsteady a normal initial reaction to Neurotin?

Regulatory documents confirm that dizziness and unsteadiness (ataxia) are very common adverse reactions. These effects are commonly observed early in the course of treatment.

How should Neurotin be stored and disposed of?

How to Store and Dispose of Neurotin?

Strict storage requirements are defined to maintain the stability and safety of Neurotin (gabapentin).

Dosage Form Maximum Storage Temperature
Capsules Below 30 C (86 F)
Tablets Below 25 C (77 F)

For stability, the medication must be kept in the original container or blister pack. To prevent accidental ingestion and misuse, all forms of Neurotin must be stored out of the sight and reach of children.

Regarding disposal, unused or expired Neurotin should not be thrown away via wastewater or household waste. Official guidance instructs users to ask a pharmacist how to safely and responsibly dispose of medicines that are no longer needed, which helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurotin found in:

A-Z Index: